Juno Therapeutics, Inc…today announced that it has received notice from the U.S. Food and Drug Administration that a clinical hold has been placed on the Phase II clinical trial of JCAR015 in adult patients with relapsed or refractory B cell acute lymphoblastic leukemia (r/r ALL), known as the “ROCKET” trial. The clinical hold was initiated after two patient deaths last week, which followed the recent addition of fludarabine to the pre-conditioning regimen.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”